Deferoxamine - ≥98.0%, high purity , CAS No.70-51-9

Item Number

D651377

• Specifications & Purity: ≥98%
• Biochemical and Physiological Mechanisms: Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine al
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads

Product Description

Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.

In Vitro

Deferoxamine (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells. Deferoxamine (100 µM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels. Deferoxamine (5, 10, 25, 50, 100 µM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs. Deferoxamine (5, 10, 25, 50, 100 µM; 7 days) induces apoptosis of MSCs. Deferoxamine (10 µM ; 3 days) influencs the expression of adhesion proteins on MSCs. Deferoxamine (100 µM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: MEFs cells Concentration: 1 mM Incubation Time: 16 h (hypoxia condition); 4 weeks (hyperglycemic conditions) Result: Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions. Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions. Western Blot AnalysisCell Line: HepG2 cells Concentration: 100 µM Incubation Time: 24 h Result: Showed a twofold increase of InsR mRNA levels in cells. Increased by twofold InsR binding activity at the half-maximal concentration of 1.1 nM. Cell Proliferation AssayCell Line: TAMSCs and BMMSCs (all isolated from Male C57BL/6J mice (8 week-old; EG-7 induced tumor model)) Concentration: 5, 10, 25, 50, 100 µM Incubation Time: 7 days (TAMSCs); 9 days (BMMSCs). Result: Inhibited the growth of TAMSCs and BMMSCs, and most cells are died at day 7 or 9 when exposed to 50 and 100 µM dose. Apoptosis AnalysisCell Line: TAMSCs, BMMSCs Concentration: 5, 10, 25, 50, 100 µM Incubation Time: 7 days Result: Exhibited proapoptotic effect on TAMSCs and BMMSCs cells. Western Blot AnalysisCell Line: TAMSCs, BMMSCs Concentration: 10 µM Incubation Time: 3 days Result: Remarkably decreased VCAM-1 expression in both TAMSCs and BMMSCs. Cell Autophagy Assay Cell Line: SH-SY5Y cells Concentration: 100 µM Incubation Time: 24 h Result: Increased the ratio of LC3-II/I, an indicator of autophagy, which effects were blocked when autophagy-related gene Beclin 1 was suppressed by Beclin 1 siRNA transfection. Caused a time and dose-dependent increase of HIF-1a, accompanied by the induction of autophagy.

In Vivo

Deferoxamine (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice . Deferoxamine (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model) . Dosage: 560.68 mg/per (10 uL of 1 mM) Administration: Drip-on; once daily for 21 days. Result: Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model. Animal Model: Male Sprague-Dawley rats (180-200 g). Dosage: 200 mg/kg Administration: Intraperitoneal injection; daily for 2 weeks. Result: Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver.

Form:Solid